Biophytis (BPTS) Stock Forecast, Price Target & Predictions
BPTS Stock Forecast
Biophytis stock forecast is as follows: an average price target of $15.00 (represents a 96.85% upside from BPTS’s last price of $7.62) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
BPTS Price Target
The average price target for Biophytis (BPTS) is $15.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $15.00. This represents a potential 96.85% upside from BPTS's last price of $7.62.
BPTS Analyst Ratings
According to 1 Wall Street analysts, Biophytis's rating consensus is 'Buy'. The analyst rating breakdown for BPTS stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Biophytis Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 21, 2024 | Joseph Pantginis | H.C. Wainwright | $15.00 | $8.22 | 82.48% | 96.85% |
The latest Biophytis stock forecast, released on Jun 21, 2024 by Joseph Pantginis from H.C. Wainwright, set a price target of $15.00, which represents a 82.48% increase from the stock price at the time of the forecast ($8.22), and a 96.85% increase from BPTS last price ($7.62).
Biophytis Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $15.00 |
| Last Closing Price | $7.62 | $7.62 | $7.62 |
| Upside/Downside | -100.00% | -100.00% | 96.85% |
In the current month, the average price target of Biophytis stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Biophytis's last price of $7.62. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 21, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Biophytis's last stock rating was published by H.C. Wainwright on Jun 21, 2024. The company gave BPTS a "Buy" rating, the same as its previous rate.
Biophytis Financial Forecast
Biophytis Revenue Forecast
| Dec 23 | |
|---|---|
| Revenue | - |
| Avg Forecast | - |
| High Forecast | - |
| Low Forecast | - |
| # Analysts | - |
| Surprise % | - |
Biophytis's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. BPTS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Biophytis EBITDA Forecast
| Dec 23 | |
|---|---|
| # Analysts | - |
| EBITDA | - |
| Avg Forecast | - |
| High Forecast | - |
| Low Forecast | - |
| Surprise % | - |
undefined analysts predict BPTS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Biophytis's previous annual EBITDA (undefined) of $NaN.
Biophytis Net Income Forecast
| Dec 23 | |
|---|---|
| # Analysts | - |
| Net Income | - |
| Avg Forecast | $-709.12K |
| High Forecast | $-709.12K |
| Low Forecast | $-709.12K |
| Surprise % | - |
Biophytis's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BPTS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Biophytis SG&A Forecast
| Dec 23 | |
|---|---|
| # Analysts | - |
| SG&A | - |
| Avg Forecast | - |
| High Forecast | - |
| Low Forecast | - |
| Surprise % | - |
Biophytis's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to BPTS last annual SG&A of $NaN (undefined).
Biophytis EPS Forecast
| Dec 23 | |
|---|---|
| # Analysts | - |
| EPS | - |
| Avg Forecast | $-0.27 |
| High Forecast | $-0.27 |
| Low Forecast | $-0.27 |
| Surprise % | - |
According to undefined Wall Street analysts, Biophytis's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BPTS previous annual EPS of $NaN (undefined).
Biophytis Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| AKTX | Akari Therapeutics | $1.57 | $12.00K | 764231.21% | - |
| CHRS | Coherus BioSciences | $0.82 | $9.00 | 997.56% | Hold |
| PCSA | Processa Pharmaceuticals | $0.90 | $9.00 | 900.00% | Buy |
| SPRO | Spero Therapeutics | $1.16 | $10.00 | 762.07% | Buy |
| IPHA | Innate Pharma | $1.49 | $10.00 | 571.14% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| RZLT | Rezolute | $4.95 | $13.50 | 172.73% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| BPTS | Biophytis | $8.22 | $15.00 | 82.48% | Buy |
| BOLT | Bolt Biotherapeutics | $0.56 | $1.00 | 78.57% | Hold |
| NRXP | NRx Pharmaceuticals | $1.23 | $2.00 | 62.60% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |